The present invention relates to biomarkers, and particularly, although not exclusively, to biomarkers of preterm birth. The biomarkers are useful, several weeks or months prior to birth, for distinguishing individuals at risk of experiencing birth before 37 weeks of gestation. The biomarkers, namely ECM1, FGA, EFEMP1, GGH, PEDF, PTN and LAMC2, are identified by a proteomics analysis, as being differentially expressed in vaginal fluid by women going to have preterm birth.
